Virginia Economic Review

As the world continues to struggle with drug supply chains and critical shortages, clusters of activity have emerged to move the needle of medication affordability and accessibility.

Recent major biopharmaceutical manufacturing announcements are positioning Virginia for a broader reshoring effort in the pharma industry. COVID-era supply chain disruptions and resulting shortages exposed the risks of over-reliance on overseas production for essential medicines.

Partnership With JMU, BRCC Helps Merck Fill Need for HPV Vaccines In 2019, Melissa Lubin learned that pharmaceutical giant Merck & Co., Inc., was competing for a billion-dollar expansion in Elkton, a town in the Shenandoah Valley.

During the COVID-19 pandemic, Virginia Tech's Rob Gourdie was busy investigating how to deliver medications more effectively.

Kimberly Kelly was a biomedical engineer at the University of Virginia (UVA), working on ways to diagnose pancreatic cancer, when she discovered a protein expressed by the cancer cells.

Despite facing an unprecedented global pandemic, executives at GlaxoSmithKline Consumer Healthcare (GSK) were able to recruit 150 new employees for the company’s research and development center in Richmond.